# OnCo record ibritumomab-tiuxetan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ibritumomab-tiuxetan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ibritumomab-tiuxetan" ;
  schema:name "Ibritumomab tiuxetan"@en ;
  schema:alternateName "Y-90 ibritumomab"@en, "Zevalin therapeutic regimen"@en, "Zevalin" ;
  schema:description "Zevalin is an antibody carrying a radioactive isotope that seeks out CD20 on lymphoma cells. It treats follicular lymphoma that has relapsed and is given as a one-off consolidation after chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/ibritumomab-tiuxetan/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibritumomab%20tiuxetan>, <https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan>, <https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Radioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)" ;
  onco:approval "US 2002: Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma", "US 2009: Consolidation after first-line chemotherapy in previously untreated follicular NHL", "EU 2004: Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008" ;
  onco:acceleratedApproval "US 2002-02-19: Relapsed or refractory low-grade follicular or transformed B-cell NHL other than rituximab-refractory follicular NHL" ;
  onco:acceleratedApprovalConfirmed "US 2009-09-03: Relapsed or refractory low-grade follicular or transformed B-cell NHL other than rituximab-refractory follicular NHL" ;
  onco:related <https://onco.cc/drugs/rituximab/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/radioimmunotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/> ;
  onco:companies <https://onco.cc/companies/acrotech-biopharma/> ;
  onco:trials <https://onco.cc/trials/nct01827605/>, <https://onco.cc/trials/nct00582166/>, <https://onco.cc/trials/nct01497275/> .